Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma
| Autor: | Hui Cong, Yafang Pan, Meihong Lu, Shaoqing Ju, Xianjuan Shen, Xudong Wang, Hongmei Chen |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine Oncology medicine.medical_specialty Clinical Biochemistry Disease Real-Time Polymerase Chain Reaction Biochemistry 03 medical and health sciences 0302 clinical medicine Downregulation and upregulation Internal medicine Tumor Cells Cultured Humans Medicine Diagnostic biomarker Multiple myeloma business.industry Biochemistry (medical) Cancer General Medicine Middle Aged medicine.disease female genital diseases and pregnancy complications Long non-coding RNA 030104 developmental biology Real-time polymerase chain reaction 030220 oncology & carcinogenesis embryonic structures Biomarker (medicine) Female RNA Long Noncoding Multiple Myeloma business |
| Zdroj: | Clinica Chimica Acta. 480:199-205 |
| ISSN: | 0009-8981 |
| DOI: | 10.1016/j.cca.2018.02.019 |
| Popis: | Circulating long noncoding RNA (lncRNA) H19 has been reported to be a biomarker for cancer monitoring. The purpose of this study was to determine whether serum lncRNA could serve as a novel biomarker for the diagnosis of multiple myeloma (MM) and evaluate its value of clinical application. In our study, the expression of lncRNA H19 was up-regulated in 80 patients with MM and MM cell lines by RT-PCR analysis. Clinicopathological analysis showed the expression level of H19 could assist clinical staging, and the severity of the disease could be roughly determined according to the amount of H19 expressed in the patient serum. This is the first report to show that H19 was expressed in the serum of MM patients, suggesting that upregulation of serum lncRNA H19 may prove to be a novel biomarker for early diagnosis and clinical treatment of MM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect